A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer

Trial Profile

A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Sorafenib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 02 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jan 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top